InvestorsHub Logo
Followers 8
Posts 628
Boards Moderated 0
Alias Born 05/26/2021

Re: None

Sunday, 07/17/2022 12:24:46 AM

Sunday, July 17, 2022 12:24:46 AM

Post# of 13742
anger COULD be directed at the FDA … as it was the FDA that moved the goal post

Dr Mikaelian has spent close to 2 decades of research and refining, developing and testing the escozine …. Bringing it to the point where many on this board only but ever first heard of them last spring when shares were 0.05 Cents … it was a low share count and with positive feedback from the fda and excitement from investors the stock jumped to 0.20 Cents

It looked at that point a stock one could “almost” guarantee doubling money on or more in a short amount of time …

However … the fda directly because of the Covid vaccine concern now on how things affect humans at the dna level … instead of pushing escozine fwd (which is how it was looking it would go ..) the fda NOW has added testing … that NO ONE could foresee (not diff management not anyone on this board … no one, as it was new and the fda states as much )

Sooooo then with bad advice a rs was written in as something that could be used if needed to help leg up to Nasdaq. (This imo was where the spiral down in the sp truly began).

Ultimately lots of very unfortunate unforeseen things ….

Do I like the current sp ? No.

However, simply “selling the company” isn’t necessarily the right solution… why?
Because literally to get a drug to the stage Medoliferx got escozine takes many years and lots of funding …
The hopeful candidate for new shared ceo is one who has experience with the fda …

MedolifeRx is a small company
They have patents and products and have an exclusive agreement with the DR

Have a good weekend
GLTA

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.